BGM Group Ltd Dossier
|
SectorHealth Care IndustryPharmaceuticals Beta (adjusted)1.54 Intrinsic Value No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference. Market Price $0.25Price as of 30 Sep 2026 Data confidence Sign in to view data confidence Market Cap $100.9M Shares Outstanding 380.6M diluted Last ex-dividend27 Feb 2023 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary BGM Group Ltd. (formerly Qilian International Holding Group Limited) is undergoing a highly speculative and risky pivot from its legacy, low-margin biopharmaceutical and chemical business in China toward AI-driven technology, intelligent robotics, and insurtech. While the legacy business has suffered a severe 46% year-over-year revenue decline to $25.1 million in FY2024, the company has embarked on an aggressive string of all-stock acquisitions (including HM Management and Wonder Dragon Global) and a highly dilutive $12 million private placement at $0.06 per share in June 2026. This massive dilution, combined with persistent regulatory reporting delays (late Form 20-F filings) and Nasdaq non-compliance notices regarding its sub-$1.00 share price, presents extreme downside risk for public shareholders. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The bear case centers on extreme shareholder dilution (with shares outstanding increasing over 100% in the past year due to all-stock acquisitions and the $12 million private placement), persistent net losses ($19.9 million trailing loss as of July 2026), and execution risks in pivoting from traditional pharmaceuticals to highly competitive AI software. Additionally, regulatory compliance risks, such as Nasdaq minimum bid price warnings and late SEC filings, pose severe downside risks. Base CaseCentral scenario The legacy pharmaceutical business continues to contract or stabilize at low margins, while the newly acquired AI and technology platforms fail to generate meaningful near-term cash flows. Shareholder value is heavily diluted by the June 2026 private placement of 200 million shares and warrants, and the company executes a reverse stock split to maintain its Nasdaq listing. Bull CaseUpside scenario The bull case relies on the successful commercialization and integration of the DuXiaoBao and Bao Wang AI platforms, leveraging partnerships with Baidu and AIFU to scale high-margin insurtech services globally. If BGM can successfully transition its legacy pharmaceutical customer base and optimize supply chains using AI, it could achieve significant margin expansion and a higher technology-sector valuation multiple. Scenarios reflect our research view at the research date. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |